Munich Re Directors Double Down With €81 Million in Stock as Price Slide Tests Resolve

Munich Re posts €1.714B Q1 profit, but shares near 52-week low amid reinsurance capacity glut. Five board members invest €81M in stock, signaling undervaluation.

Munich Re posted a first-quarter profit of €1.714 billion, a 56.6% jump from €1.094 billion a year earlier, and still the stock sits close to its 52-week low. The disconnect between operational strength and market sentiment has become so severe that five board members just spent roughly €81 million of their own money buying shares near €467 apiece — a rare show of conviction from a management team that has also been deliberately shrinking the company’s underwriting footprint.

The source of the market’s unease is plain. Global reinsurance capital has surged to a record $805 billion, according to broker Howden Re, flooding the sector with capacity. In the property-catastrophe line, rates fell 15–20% at the June renewal season, with loss-free treaties suffering even sharper drops. Munich Re responded by cutting its own written volume 18.5% at the April renewals, accepting only business that met its return hurdles. The risk-adjusted prices it did take were down just 3.1%, a testament to selective underwriting, but the market still marks the stock down.

That selectivity comes with a hidden cost. Munich Re slashed its retrocession — external reinsurance that covers its own exposure — by 60% to only $600 million. The company keeps more premium but carries far greater net risk, particularly as the North Atlantic hurricane season intensifies. A single major storm could now hit the balance sheet harder than in prior years, amplifying the anxiety that has pushed the shares 15% lower since January 1 to around €465.80. The 52-week trough of €437.50 was touched on June 2.

Against that backdrop, the insider buying spree demands attention. Chief Executive Andrew Buchanan acquired 172,728 shares at an average price of €466.83 in an off-exchange transaction. Four other board members followed: Dr. Achim Kassow took 300 shares at €470, Stefan Golling 420 at roughly €476, Dr. Markus Rieß 500 at €476.50, and Mari-Lizette Malherde invested nearly €197,800 at around €479. In total, 174,361 shares changed hands, representing a direct bet that the current price undervalues the company’s long-term earnings power.

The board is not the only party leaning into the weakness. Munich Re’s €2.25 billion buyback programme, running until the annual general meeting in April 2027, is already providing a floor. The current €900 million tranche expires on August 21, 2026, and the company bought its cheapest shares so far on June 3 at €440.44. Yet even as management scoops up equity, some institutional holders are heading the other way. JPMorgan Asset Management slipped below the 3% notification threshold to 2.99% on May 21, citing “acting in concert” among its units — a move that looks more like portfolio rebalancing than a strategic exit. Capital Group also trimmed, reducing its stake to 2.89%.

The next test comes in July, when Munich Re faces another renewal round. The company expects stable pricing, a view that, if borne out, would remove one of the main drags on the shares. Analysts at Jefferies argue that only a global insured loss above $100 billion could reignite hard pricing across the industry — a threshold that would be grim for the broader market but could, ironically, lift Munich Re’s own rates.

The half-year report on August 7 will offer the first real check on the company’s increased retained risk. Until then, the tension between a boardroom spending millions on its own stock and a market that refuses to look past softer rates and storm clouds will define the narrative. For now, Munich Re’s directors have placed a heavy bet that discipline — and the buyback — will eventually win the day.